Shell Asset Management Co. Has $1.54 Million Stock Holdings in Zoetis Inc. $ZTS

Shell Asset Management Co. grew its stake in Zoetis Inc. (NYSE:ZTS) by 58.1% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 9,890 shares of the company’s stock after buying an additional 3,636 shares during the period. Shell Asset Management Co.’s holdings in Zoetis were worth $1,542,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in ZTS. Brighton Jones LLC increased its stake in shares of Zoetis by 180.4% in the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock valued at $754,000 after buying an additional 2,978 shares during the period. Wedmont Private Capital grew its stake in Zoetis by 5.0% during the first quarter. Wedmont Private Capital now owns 2,563 shares of the company’s stock worth $422,000 after purchasing an additional 122 shares during the period. Miracle Mile Advisors LLC grew its stake in Zoetis by 42.1% during the first quarter. Miracle Mile Advisors LLC now owns 2,373 shares of the company’s stock worth $391,000 after purchasing an additional 703 shares during the period. OLD National Bancorp IN grew its stake in Zoetis by 28.4% during the first quarter. OLD National Bancorp IN now owns 1,993 shares of the company’s stock worth $328,000 after purchasing an additional 441 shares during the period. Finally, Courier Capital LLC grew its stake in Zoetis by 29.6% during the first quarter. Courier Capital LLC now owns 1,972 shares of the company’s stock worth $325,000 after purchasing an additional 450 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Up 0.6%

Shares of NYSE:ZTS opened at $143.61 on Thursday. The business’s 50 day simple moving average is $149.41 and its two-hundred day simple moving average is $154.74. The firm has a market cap of $63.65 billion, a P/E ratio of 24.72, a PEG ratio of 2.29 and a beta of 0.90. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. Zoetis Inc. has a 52-week low of $139.34 and a 52-week high of $196.55.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.14. The business had revenue of $2.46 billion for the quarter, compared to analyst estimates of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The company’s quarterly revenue was up 4.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, research analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on ZTS shares. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Zoetis in a research note on Wednesday. Leerink Partnrs cut Zoetis from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 17th. Piper Sandler raised their target price on Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research note on Monday, August 11th. Leerink Partners cut Zoetis from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. Finally, Stifel Nicolaus lowered Zoetis from a “buy” rating to a “hold” rating and cut their price target for the stock from $165.00 to $160.00 in a report on Wednesday, June 18th. Five research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat, Zoetis has a consensus rating of “Moderate Buy” and an average price target of $200.88.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.